Publikationen
Ausgewählte Publikationen (PubMed)
Entzündliche Schmerzen
Jonas R, Schmelz M. Sensitization of supra-threshold pain responses—Translational aspects and mechanisms. Front. Netw. Physiol., 2022. Sec. Systems Interactions and Organ Networks. https://doi.org/10.3389/fnetp.2022.1078890 (Review)
Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108:191-200. doi: 10.1002/cpt.1830.
Theken KN, Hersh EV, Lahens NF, Lee HM, Li X, Granquist EJ, Giannakopoulos HE, Levin LM, Secreto SA, Grant GR, Detre JA, FitzGerald GA, Grosser T*, Farrar JT*. Variability in the analgesic response to ibuprofen is associated with cyclooxygenase activation in inflammatory pain. Clin Pharmacol Ther. 2019;106:632-641. doi: 10.1002/cpt.1446. [*) equal contribution]
Grosser T, Theken KN, FitzGerald GA. Cyclooxygenase inhibition: Pain, inflammation, and the cardiovascular system. Clin Pharmacol Ther. 2017;102:611-622. doi: 10.1002/cpt.794. (Review)
Grosser T, Woolf CJ, FitzGerald GA. Time for nonaddictive relief of pain. Science. 2017;355:1026-1027. doi: 10.1126/science.aan0088. (Editorial)
Kardiovaskuläres System
Katherine N. Theken, Soumita Ghosh, Carsten Skarke, Susanne Fries, Nicholas F. Lahens, Dimitra Sarantopoulou, Gregory R. Grant, Garret A. FitzGerald, Tilo Grosser
Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen.
medRxiv 2024.05.30.24308244; doi: https://doi.org/10.1101/2024.05.30.24308244
https://www.medrxiv.org/content/10.1101/2024.05.30.24308244v1
Tang SY, Lordan R, Meng H, Auerbach BJ, Hennessy EJ, Sengupta A, Das US, Joshi R, Marcos-Contreras OA, McConnell R, Grant GR, Ricciotti E, Muzykantov VR, Grosser T, Weiljie AM, FitzGerald GA.
Differential Impact In Vivo of Pf4-ΔCre-Mediated and Gp1ba-ΔCre-Mediated Depletion of Cyclooxygenase-1 in Platelets in Mice.
Arterioscler Thromb Vasc Biol. 2024 Jun;44(6):1393-1406.
doi: 10.1161/ATVBAHA.123.320295. Epub 2024 Apr 25. PMID: 38660804; PMCID: PMC11138953. https://www.ahajournals.org/doi/10.1161/ATVBAHA.123.320295
Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111:16830-5. doi: 10.1073/pnas.1406997111.
Grosser T*, Fries S*, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. [*) equal contribution]
Fries S*, Grosser T*, Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006;130:55-64. doi: 10.1053/j.gastro.2005.10.002. PMID: 16401468. [*) equal contribution]
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15. doi: 10.1172/JCI27291. (Review)
COVID-19
Lordan R, Prior S, Hennessy E, Naik A, Ghosh S, Paschos GK, Skarke C, Barekat K, Hollingsworth T, Juska S, Mazaleuskaya LL, Teegarden S, Glascock AL, Anderson S, Meng H, Tang SY, Weljie A, Bottalico L, Ricciotti E, Cherfane P, Mrcela A, Grant G, Poole K, Mayer N, Waring M, Adang L, Becker J, Fries S, FitzGerald GA, Grosser T. Considerations for the safe operation of schools during the coronavirus pandemic. Front Public Health. 2021;9:751451. doi: 10.3389/fpubh.2021.751451. (Review)
Lordan R, FitzGerald GA, Grosser T. Reopening schools during COVID-19. Science. 2020;369:1146. doi: 10.1126/science.abe5765. (Editorial)